Many bacterial infections can be treated with the use of antibiotics. These medications continue to reduce morbidity and mortality; unfortunately, their use has brought about drug-resistant pathogens that produce difficult-to-treat infections, which require more extreme treatments. New antibiotics are needed to combat this ever-evolving resistance pathogenesis.
Infections by resistant bacteria have plagued modern civilization progressing from penicillin-resistant Staphylococcus aureus in the 1950s, to Pseudomonas aeruginosa infections in cancer patients in the 1950s, methicillin-resistant Staphylococcus aureus (MRSA) in the 1960s, and multidrugresistant Gram-negative bacteria in the 2000s. 1 The Centers for Disease Control and Prevention (CDC) reports that over 2 million Americans are infected with antibiotic resistant infections each year with 23 000 deaths resulting from these infections. MRSA represents a leading cause of health careassociated infections that result in over 11 000 fatalities per year.
2 Vancomycin-resistant enterococci (VRE) have up to a 77% resistance rate against vancomycin. 2 The CDC reports that 30% of severe Streptococcus pneumoniae cases involve bacteria that are completely resistant to one or more clinically relevant antibiotics. Studies have estimated that antibiotic resistance causes at least an additional $20 billion in direct health care costs, with costs from lost productivity as high as $35 billion each year.
2 To counteract bacterial evolution, the CDC has identified 4 critical actions to limit drug resistance: preventing infections, tracking infections, improving antibiotic stewardship, and developing new drugs and diagnostic tests. 
Current Treatment
In life-threatening infections that will likely result in prolonged therapy, isolating the actual pathogen is critical for treatment. Even though the ideal diagnosis is based on microbial cultures or serologic testing, many times the clinical presentation guides treatment. Initiation of antimicrobial treatment should be determined by the severity of the situation, with immediate initiation occurring in critically ill patients. Beginning with empiric therapy and then narrowing treatment as culture and sensitivity results are obtained should be the goal to reduce cost and toxicity, while helping to prevent the emergence of antimicrobial resistance. 4 Currently, linezolid, dalbavancin, oritavancin, telavancin, daptomycin, and tigecycline are second-line antibiotics reserved for treatment of resistant organisms. Linezolid, dalbavancin, oritavancin, telavancin, and daptomycin are active against MRSA and VRE. Tigecycline works against MRSA, VRE, Acinetobacter baumannii and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae. Colistin has reemerged as a treatment for ESBL Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii in intensive care patients. 5 According to the CDC, more than 13% of an estimated 51,000 health care-associated Pseudomonas aeruginosa involve multidrug-resistant strains. Acinetobacter affects a smaller population of 12,000; however, 63% of these cases involve multidrug-resistant organisms. 
New Treatment Options
To stay ahead of drug-resistant bacteria, researchers are developing new antibiotics (Table 1) and looking for synergistic combinations of older drugs. Beta-lactam antibiotics such as carbapenem/beta-lactamase inhibitors, new cephalosporins, and carbapenem dehydropeptidase inhibitors are being tested in an effort to combat the evolution of drugresistant bacteria. Researchers are looking into combination carbapenem/beta-lactamase inhibitors as well as a triple combination of cilastatin/imipenem/relebactam for the treatment of multidrug-resistant bacteria. New cephalosporins include ceftobiprole and cefiderocol. Studies have shown that the drugs listed in Table 1 are noninferior to current therapies. Phase III trials are currently being conducted that will help determine the safety of cefiderocol and imipenem/cilastatin/relebactam. New antibiotics also include a systemic dosage of fusidic acid; new tetracyclines, eravacycline and omadacycline; a new aminoglycoside, plazomicin; a diaminopyrimidine dihydrofolate reductase inhibitor, iclaprim; and the first pleuromutilin antibiotic, lefamulin. Note. Information adapted from the Prescribe Right Pharmaceutical Pipeline Tracker database. 7 FDA = Food and Drug Administration; DHHS = Department of Health and Human Services; BARDA = Biomedical Advanced Research and Development Authority; UTI = urinary tract infection; cIAI = complicated intra-abdominal infections; ABSSSI = acute bacterial skin and skin structure infections; CAP = community-acquired pneumonia.
